Welcome to our dedicated page for Schrodinger SEC filings (Ticker: SDGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Schrödinger, Inc. (SDGR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered tools that help interpret key documents. As a Nasdaq-listed issuer, Schrödinger files current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, among other documents, to provide transparency into its operations, governance and financial condition.
Recent Form 8-K filings illustrate the range of topics covered in SDGR’s regulatory reporting. The company has furnished press releases announcing quarterly financial results under Item 2.02, giving detail on software revenue, drug discovery revenue, software gross margin, operating expenses, cash position and non-GAAP measures. Other 8-K filings describe matters such as the submission of proposals to stockholders at the annual meeting, voting outcomes for director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm.
Schrödinger has also used Form 8-K to disclose executive compensation and separation arrangements under Item 5.02, including a separation and release of claims agreement with a former executive vice president and chief financial officer. These filings outline severance-related payments, equity vesting terms, COBRA-related benefits and other contractual provisions, providing insight into the company’s executive compensation framework.
On Stock Titan, users can review SDGR’s 10-K and 10-Q filings for detailed discussions of its software and drug discovery activities, risk factors, segment information and accounting policies. AI-powered summaries help explain lengthy filings by highlighting important sections, such as revenue breakdowns between software and drug discovery, non-GAAP reconciliations and disclosures related to collaborations and equity investments. The platform also surfaces Form 4 insider transaction reports, allowing users to track equity awards and share transactions by directors and officers.
With real-time updates from EDGAR and AI-generated overviews, the Schrödinger SEC filings page is intended to make it easier to navigate complex regulatory documents, compare periods and understand how SDGR’s computational platform, collaborations and therapeutics portfolio are reflected in its official disclosures.
Schrödinger, Inc. (SDGR) reported Q3 2025 results with total revenue of $54,324, up from $35,290 a year ago, and a narrower net loss of $32,795 versus $38,136. For the first nine months, revenue reached $168,634 compared with $119,222, while net loss improved to $135,776 from $146,907.
Software products and services delivered $40,858 in Q3, led by on-premise software $15,928, hosted software $11,585, maintenance $6,826, professional services $1,589, and software contributions $4,930. Drug discovery revenue was $13,466, including $13,008 from services and $458 from contributions.
Operating expenses declined year over year, with research and development $42,757, sales and marketing $9,524, and general and administrative $21,705. Cash and cash equivalents were $172,120 and marketable securities $219,113 at quarter end. Deferred revenue totaled $82,283 short‑term and $92,390 long‑term; the company expects to recognize approximately 47% of its September 30, 2025 deferred revenue in the next 12 months.
Collaboration revenue included $8.8 million from Novartis in Q3 and $0.7 million from the BMS agreement. As of October 29, 2025, there were 64,500,510 common shares and 9,164,193 limited common shares outstanding.
Schrödinger, Inc. (SDGR) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference in this report.
The company states the information in this report, including Exhibit 99.1, is being furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liability and will not be incorporated into other filings unless specifically referenced. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Schrodinger, Inc. (SDGR) reported an insider transaction by its Chief Medical Officer, Margaret Dugan. On 10/16/2025, she sold 1,395 shares of common stock at $21.066 per share, coded “S.”
The filing states the sale was executed under a Rule 10b5-1 automatic instruction adopted on November 13, 2023, and was a broker-assisted sale to cover withholding taxes upon the vesting of restricted stock units. Following the sale, she beneficially owns 24,574 shares, which include 20,000 unvested RSUs. Ownership is listed as direct.
Schrödinger, Inc. filed details of its separation and release of claims agreement with former Executive Vice President and Chief Financial Officer Dr. Geoffrey Porges, following his previously disclosed departure. The agreement confirms severance terms that are described as substantially comparable to those in his 2022 employment agreement and the company’s executive severance plan.
Under the agreement, Dr. Porges will receive salary continuation for nine months, company-paid portions of COBRA health and dental premiums for up to 12 months, and accelerated vesting of the stock option award granted when he joined the company. He is also eligible for a prorated 2025 annual bonus, an extension of the post-separation exercise period for his vested stock options, and a lump-sum payment if he joins a new employer’s health plans before the COBRA period ends.
All benefits are conditioned on Dr. Porges not revoking the agreement during a seven-day revocation period and complying with ongoing obligations, including confidentiality, inventions, non-solicitation, and mutual non-disparagement and release of claims between him and the company.
Schrodinger Director Jeffrey Chodakewitz reported two significant equity transactions on June 18, 2025:
- Received 5,997 Restricted Stock Units (RSUs) at $0, bringing total beneficial ownership to 17,247 shares. RSUs vest after 12 months or by next annual stockholder meeting, with settlement deferred until separation from service or change in control.
- Granted stock options to purchase 9,341 shares at an exercise price of $21.05 per share, expiring June 18, 2035. Options follow the same vesting schedule as RSUs.
Both awards were granted under the company's 2022 Equity Incentive Plan. The transactions represent standard board of director compensation, with vesting contingent on continued service. The Form 4 was filed by Donald Shum as attorney-in-fact on June 20, 2025.
Schrodinger Director Gary Sender reported significant equity compensation transactions on June 18, 2025. The insider received two key awards:
- 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. These RSUs vest after 12 months or by the next annual stockholder meeting, whichever comes first.
- Stock Options to purchase 9,341 shares at an exercise price of $21.05 per share. These options expire on June 18, 2035 and follow the same vesting schedule as the RSUs.
Both awards are subject to continued service requirements and were granted as part of the company's director compensation program. The transactions were reported via Form 4 filing, with Donald Shum signing as attorney-in-fact for Gary Sender on June 20, 2025.
Schrodinger Director Michael Lynton reported significant equity compensation grants on June 18, 2025, consisting of two main components:
- 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. These RSUs vest after 12 months or by the next annual stockholder meeting, with deferred settlement until 30 days after separation or change in control.
- 9,341 Stock Options with a $21.05 exercise price, expiring June 18, 2035. The options follow the same vesting schedule as the RSUs - one year or next annual meeting, subject to continued service.
The Form 4 filing, executed by Donald Shum as attorney-in-fact on June 20, 2025, reflects standard director compensation practices and aligns the director's interests with shareholders through equity-based awards. All securities are held directly with no indirect ownership reported.
Schrodinger Director Receives Equity Compensation
Director Bridget van Kralingen received new equity awards from Schrodinger (SDGR) on June 18, 2025, consisting of:
- 1,499 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total RSU holdings to 11,499 units
- 2,335 Stock Options with an exercise price of $21.05, expiring June 18, 2035
Both awards vest on the earlier of (1) the twelve-month anniversary of the grant date or (2) the next annual stockholder meeting, subject to continued service. RSU settlement is deferred until 30 days after separation from service or a change in control event. The grants were made under the company's 2022 Equity Incentive Plan. This filing represents standard board of director compensation rather than open market transactions.
Schrodinger (SDGR) director Nancy Thornberry reported two significant equity compensation grants on June 18, 2025:
- 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. RSUs vest after 12 months or by the next annual stockholder meeting, with settlement deferred until separation from service or change in control.
- 9,341 Stock Options with a $21.05 exercise price, expiring June 18, 2035. Options follow the same vesting schedule as the RSUs.
These grants represent standard director compensation aligned with the company's equity incentive plan. The transaction was executed directly, with no indirect ownership reported. All securities were acquired at $0 cost as part of director compensation.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
